Saudi Arabia Plans $23 Billion Remake of Its Capital Riyadh


Saudi Arabia plans $23 billion remake of its capital Riyadh. Saudi Arabia government made this announcement as a part of a massive beautification project for its capital.

This plan aims to improve quality of life for the residents as well as support the opening up of the country’s tourism sector. The project will include recreational areas, more than 1,000 art installations, and green space. In addition, under the Kingdom’s Vision 2030 initiative, the plan will create private investment opportunities.  
A goal of this initiative is to add private sector jobs and expand oil-rich monarchy’s revenue sources.

The news agency reported that work will start in the second half of 2019 with creating 70,000 jobs. The kingdom has pushed different high-profile events such as the Formula E championship that it hosted last December. Now, preparing opening up of World Wrestling Entertainment tournaments.

“In Vision 2030 and in the Crown Prince’s dynamic vision, tourism is next, because it’s a tremendous generator of jobs,” Jerry Inzerillo, CEO of Diriyah Gate Development Authority said on Tuesday.

Saudi Arabia still faces the reputational consequences following the October murder of Saudi journalist Jamal Khashoggi. Additionally, although the country has ended the long-standing ban on women driving, the country is known for its poor track record on women’s issues. However, the kingdom can refocus its image and move by winning foreign investment for tourism developments.

Inzerillo said, “Every million people that come, 119,000 new jobs. We will attract 7 million people here by 2023,” adding, “We’re on a very fast track.”

Do Sit-Stand Desks Help Lose Weight


Do sit-stand desks help lose weight? A new research looked at health benefits of standing desk. Several studies have shown that a sedentary lifestyle can lead to health issues such as heart disease, type 2 diabetes, obesity, and cancer.

Now, latest study has reported 430,000 deaths associated to excessive sitting. The study explains that sitting for longer time can affect body’s ability to control blood pressure, blood sugar levels, and metabolize fat.

Some studies have shown that sit-stand desks help reduce more calories. It also suggests that this type of furniture can help in the weight loss process.

However, a new research which analyzed the benefits of sit-stand desks challenges the existing views. April Chambers, an assistant professor of bioengineering at the University of Pittsburgh in Pennsylvania led this new review.

The researcher explains that past studies have only scratched the surface of this topic of sit-stand desks

Chambers analyzed the effects of standing desks on six factors including physiological, behavior, discomfort, physiological, posture, and work performance.

“There are health benefits to using sit-stand desks, such as a small decrease in blood pressure or low back pain relief, but people simply are not yet burning enough calories to lose weight with these devices.”

The researchers found that sit-stand desk had no beneficial effects on weight loss or obesity.

“In order to achieve positive outcomes with sit-stand desks, we need a better understanding of how to properly use them; like any other tool, you have to use it correctly to get the full benefits out of it,” April Chambers explained.

What Role Does Cancer Drug Play In Parkinson’s Disease?

What role do cancer drug play in Parkinson’s disease? Many studies have shown that the leukemia drug nilotinib may relieve symptoms of Parkinson’s disease.

Now in a new study, the researchers explained how this drug is effective against toxic protein as well as increases dopamine levels in the brain.

Loss of dopamine is associated to Parkinson’s disease. Another hallmark of the condition includes presence of the protein alpha-synuclein in the brain of Lewy bodies. Toxic clumps of the toxic alpha-synuclein blocks the brain’s ability to use dopamine.

In a new experiment, the researchers used nilotinib to see its effects. The team found that a single dose of nilotinib reduced the toxic alpha-synuclein.

Parkinson’s disease is a brain condition that affects movements. The symptoms include shaking, stiffness, difficulty with walking and talking, and impaired coordination and balance. Other symptoms are depression, fatigue, sleep disruption, emotional changes,   skin complaints, urinary problems, and constipation.

In the United States, Parkinson’s disease will affect almost 1 million people by 2020, the Parkinson’s Foundation estimated.

In a new study, the investigators found that levels of dopamine metabolites was higher in those who received the nilotinib than those who took the placebo.

“This is exciting because this kind of potential treatment for Parkinson’s could increase use of a patient’s own dopamine instead of using or periodically increasing drugs that mimic dopamine,” said senior study author Dr. Charbel Moussa, a scientific and clinical research director of GUMC’s Translational Neurotherapeutics Program.

Dr. Charbel Moussa and his team explained their findings in a paper that now appears in journal Pharmacology Research & Perspectives.